Notification requirements for clinical trials involving human medicinal products containing or consisting of GMOs
The GMO aspects of clinical trials involving human medicinal products containing or consisting of GMOs are regulated under the deliberate release framework (Directive 2001/18- Part B).
The European Commission created a Questions and Answers document addressing the interplay between the medicinal products framework and the GMO framework.
Member States in conjunction with the Commission have generated application forms in respect of:
These common application forms, good practice documents (where applicable) and the Q&A document may all be retrieved from European Commission webpages dedicated to ATMP. These documents have been endorsed by the Irish competent authority.
The ATMP webpage also provides a link to a repository of national regulatory requirements in respect of the GMO aspects of clinical trials with medicinal products that contain or consist of GMOs.
Notifications seeking authorization under clinical trials and under GMO frameworks can be submitted in parallel.
Additional notification requirements include:
The deliberate release of a combination of GMOs on the same site, or a GMO or a combination of GMOs on different sites, may be notified to the EPA in the same notification, provided that: